TARA

Protara is a pre-revenue, clinical-stage biopharma, so the headline P/S of 74.5x (built off a stale FY2014 $2.95M figure) is meaningless — this is a pipeline option, not an earnings story. The economics are what you'd expect: FY2025 net loss of -$57.4M (widening 28.8% YoY), operating loss -$64.5M driven by R&D up 34.5% to $42.6M as TARA-002 (NMIBC and lymphatic malformations) and IV Choline Chloride advance, operating cash burn of -$56.4M, and an accumulated deficit of -$302.4M. Management is explicit that it expects 'significant expenses and increasing operating losses for at least the next few years,' so losses and further dilution are the base case, not a risk.

What keeps this from an 'avoid' is the balance sheet. Liabilities are just $13.1M against $196M of equity (0.07x liabilities/equity) with no debt, and MD&A discloses ~$197.9M in unrestricted cash, cash equivalents and marketable debt securities as of 12/31/25 (the $49.7M XBRL cash line is only the cash sliver — the rest sits in current-asset securities within the $160M current-asset base). Against a $220M market cap, that means the market ascribes only ~$22M of enterprise value to the entire pipeline, and roughly 3–3.5 years of runway at the current burn. That is a genuinely defensive setup for a name in this category: the downside is cushioned by near-net-cash pricing.